Baxter International Aktie
| 33,22USD | 0,24USD | 0,71% |
WKN: 853815 / ISIN: US0718131099
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,21 |
| The Vanguard Group, Inc. | 11,36 |
| Vanguard Group, Inc. (Subfiler) | 11,36 |
| Dodge & Cox | 8,74 |
| Dodge & Cox | 8,74 |
| Pzena Investment Management LLC | 6,36 |
| Pzena Investment Management, Inc. | 6,32 |
| Dodge & Cox Stock Fund | 5,89 |
| State Street Corp. | 4,27 |
| BlackRock Fund Advisors | 3,44 |
| Vanguard Dividend Growth Fund | 3,25 |
| Vanguard Total Stock Market ETF | 3,16 |
| BlackRock Advisors LLC | 2,90 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2,77 |
| Vanguard 500 Index Fund | 2,65 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 50 000 | 50 000 | 60 000 | 60 000 | 60 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,23 | 0,23 | 0,21 | 0,25 | 0,25 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7 503 | 8 411 | 8 872 | 8 011 | 9 600 |
| Summe Anlagevermögen | 10 690 | 11 608 | 24 649 | 20 276 | 18 676 |
| Summe Aktiva | 18 193 | 20 019 | 33 521 | 28 287 | 28 276 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 5 961 | 6 804 | 18 310 | 17 213 | 14 364 |
| Summe Fremdkapital | 10 281 | 11 293 | 24 400 | 22 392 | 19 808 |
| Summe Eigenkapital | 7 912 | 8 726 | 9 121 | 5 895 | 8 468 |
| Summe Passiva | 18 193 | 20 019 | 33 521 | 28 287 | 28 276 |
Adresse
| One Baxter Parkway, 60015-4625 Deerfield | |
| Telefon | +1 (224) 948-2000 |
| Internet | http://www.baxter.com |
Management
|
Alok Sonig
Executive VP & President-Pharmaceuticals |
|
Amy A. McBride-Wendell
Independent Director |
|
Angela B. Lee
Chief Diversity Officer |
|
Caitlin Kelly
Manager-Finance Team |
|
Catherine R. Smith
Independent Director |
|
Cathy R Smith
Director |
|
Charles R. Patel
Chief Information Officer & Senior Vice President |
|
Christopher A. Toth
CEO-Renal Care & Acute Therapies businesses |
|
Clare Trachtman
Vice President-Investor Relations |
|
D. Brent Shafer
Lead Independent Director |
|
Darren Evans
Vice President-Global Technical Services |
|
David S. Rosenbloom
Executive Vice President & General Counsel |
|
David S. Wilkes
Independent Director |
|
Ellen K. Bradford
Secretary & Senior Vice President |
|
Gerard Greco
Chief Quality Officer & Senior Vice President |
|
Heather Knight
EVP, President-Medical Products & Therapies |
|
Heather Wechet
VP-Talent Management & Employee Relations |
|
James W. Borzi
Chief Supply Chain Officer & Executive VP |
|
Jeanne K. Mason
Chief Human Resources Officer & Executive VP |
|
Jeffrey A. Craig
Director |
|
Joel Todd Grade
Executive VP, Chief Financial & Accounting Officer |
|
José E. Almeida
Chairman, President & Chief Executive Officer |
|
Karen L. Leets
Treasurer & Senior Vice President |
|
Lynn Pawelski
Vice President-Global Regulatory Affairs |
|
Nancy M. Schlichting
Independent Director |
|
Nicolas Henry Roelofs
Development Manager |
|
Patricia B. Morrison
Independent Director |
|
Peter M. Wilver
Independent Director |
|
Reaz Rasul
EVP, President-Healthcare Systems & Technologies |
|
Stacey T. Eisen
Chief Communications & Corporate Marketing Officer |
|
Stephen H. Rusckowski
Independent Director |
|
Stephen Newman Oesterle
Independent Director |
|
Tobi Karchmer
SVP, Chief Medical & Scientific Officer |
|
William A. Ampofo
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
